Published in Cancer Res on April 01, 2004
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol (2006) 1.82
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2013) 1.51
Diagnosis of hepatocellular carcinoma. World J Gastroenterol (2009) 1.39
Glypican-3: a new target for cancer immunotherapy. Eur J Cancer (2010) 1.30
Early HCC: diagnosis and molecular markers. J Gastroenterol (2009) 1.12
Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC. Liver Cancer (2015) 1.10
Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Neoplasia (2011) 1.09
Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol (2009) 1.09
Recombinant soluble glypican 3 protein inhibits the growth of hepatocellular carcinoma in vitro. Int J Cancer (2011) 0.99
Oncofetal protein glypican-3 in testicular germ-cell tumor. Virchows Arch (2006) 0.96
Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett (2013) 0.95
Signals and cells involved in regulating liver regeneration. Cells (2012) 0.94
Glypican-3 as a serum marker for hepatocellular carcinoma. Cancer Res (2005) 0.94
Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges. World J Gastroenterol (2007) 0.94
Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev (2005) 0.93
The role of glypican-3 in regulating Wnt in hepatocellular carcinomas. Cancer Rep (2011) 0.92
Advances in liver cancer antibody therapies: a focus on glypican-3 and mesothelin. BioDrugs (2011) 0.87
Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev (2013) 0.85
Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol (2013) 0.84
The application of a three-step serum proteome analysis for the discovery and identification of novel biomarkers of hepatocellular carcinoma. Int J Proteomics (2012) 0.84
Expression of glypican 3 in placental site trophoblastic tumor. Diagn Pathol (2010) 0.83
Early transcriptional responses of HepG2-A16 liver cells to infection by Plasmodium falciparum sporozoites. J Biol Chem (2011) 0.83
Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol (2016) 0.82
Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol (2014) 0.82
Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma. PLoS One (2014) 0.82
Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol (2010) 0.81
Surveillance and diagnosis of hepatocellular carcinoma in patients with cirrhosis. World J Hepatol (2009) 0.81
Hepatocellular tumors: immunohistochemical analyses for classification and prognostication. Chin J Cancer Res (2011) 0.80
Discovery of a new biomarker for gastroenterological cancers. J Gastroenterol (2005) 0.78
Can serum glypican-3 be a biomarker for effective diagnosis of hepatocellular carcinoma? A meta-analysis of the literature. Dis Markers (2014) 0.77
An Overview of Biomarkers and Molecular Signatures in HCC. Cancers (Basel) (2010) 0.77
Validation of glypican-3-specific scFv isolated from paired display/secretory yeast display library. BMC Biotechnol (2012) 0.76
Regulation of TGFβ superfamily signaling by two separable domains of glypican LON-2 in C. elegans. Worm (2013) 0.76
Tailored algorithms for hepatocellular carcinoma surveillance: Is one-size-fits-all strategy outdated? Curr Hepatol Rep (2017) 0.75
Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization. J Cancer (2016) 0.75
Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis. Clin Mol Hepatol (2016) 0.75
Characterization of a new monoclonal anti-glypican-3 antibody specific to the hepatocellular carcinoma cell line, HepG2. World J Hepatol (2017) 0.75
Proteoglycan-based diversification of disease outcome in head and neck cancer patients identifies NG2/CSPG4 and syndecan-2 as unique relapse and overall survival predicting factors. BMC Cancer (2015) 0.75
Glypican 3 as a Serum Marker for Hepatoblastoma. Sci Rep (2017) 0.75
Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
Can glypican-3 be a disease-specific biomarker? Clin Transl Med (2017) 0.75
Glypican-3-Expressing Hepatocellular Carcinoma in a Non-Cirrhotic Patient with Nonalcoholic Steatohepatitis: Case Report and Literature Review. Gastroenterology Res (2010) 0.75
Biomarkers for Hepatocellular Carcinoma. Biomark Cancer (2017) 0.75
Early liver cancer: concepts, diagnosis, and management. Int J Clin Oncol (2005) 0.75
Global variation in copy number in the human genome. Nature (2006) 57.50
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
International network of cancer genome projects. Nature (2010) 20.35
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature (2007) 13.56
Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature (2008) 12.01
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
Copy number variation: new insights in genome diversity. Genome Res (2006) 8.66
Genome assembly comparison identifies structural variants in the human genome. Nat Genet (2006) 6.93
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol (2003) 6.14
Genome-wide detection of human copy number variations using high-density DNA oligonucleotide arrays. Genome Res (2006) 5.97
Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol (2006) 5.82
Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med (2011) 5.66
Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63
Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev (2005) 5.50
The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science (2008) 4.94
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature (2004) 4.92
Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology (2008) 4.61
Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet (2013) 4.61
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med (2002) 4.25
Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg (2005) 4.13
Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene (2006) 4.13
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A (2003) 4.03
Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics (2005) 3.92
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell (2012) 3.90
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature (2009) 3.86
High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86
One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg (2003) 3.84
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis (2011) 3.74
Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology (2006) 3.68
Osteoprotection by semaphorin 3A. Nature (2012) 3.40
The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30
A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem (2003) 3.19
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
NFAT and Osterix cooperatively regulate bone formation. Nat Med (2005) 2.99
Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res (2005) 2.97
Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun (2005) 2.85
CARAT: a novel method for allelic detection of DNA copy number changes using high density oligonucleotide arrays. BMC Bioinformatics (2006) 2.82
Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest (2007) 2.81
Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med (2012) 2.80
Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem (2004) 2.72
Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem (2004) 2.66
Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol (2008) 2.64
Architectural roles of multiple chromatin insulators at the human apolipoprotein gene cluster. EMBO J (2009) 2.56
Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum Mol Genet (2006) 2.51
Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res (2002) 2.49
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab (2011) 2.42
Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1. Nat Cell Biol (2008) 2.35
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell (2004) 2.31
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res (2007) 2.29
The murine homolog of SALL4, a causative gene in Okihiro syndrome, is essential for embryonic stem cell proliferation, and cooperates with Sall1 in anorectal, heart, brain and kidney development. Development (2006) 2.27
Multiple renal cysts, urinary concentration defects, and pulmonary emphysematous changes in mice lacking TAZ. Am J Physiol Renal Physiol (2008) 2.24
An efficient nonviral method to generate integration-free human-induced pluripotent stem cells from cord blood and peripheral blood cells. Stem Cells (2013) 2.18
A wave of nascent transcription on activated human genes. Proc Natl Acad Sci U S A (2009) 2.18
Three Drosophila EXT genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans. Development (2003) 2.18
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet (2013) 2.14
Operative morbidity of living liver donors in Japan. Lancet (2003) 2.13
G-CSF stimulates angiogenesis and promotes tumor growth: potential contribution of bone marrow-derived endothelial progenitor cells. Biochem Biophys Res Commun (2002) 2.13
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals. Cell (2008) 2.13
BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem (2008) 2.12
Regeneration and function of hemiliver graft: right versus left. Surgery (2006) 2.12
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Vascular endothelial growth factor- and thrombin-induced termination factor, Down syndrome critical region-1, attenuates endothelial cell proliferation and angiogenesis. J Biol Chem (2004) 2.05
Vitamin E decreases bone mass by stimulating osteoclast fusion. Nat Med (2012) 2.04
Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery (2008) 2.04
Bloodless liver resection using the monopolar floating ball plus ligasure diathermy: preliminary results of 16 liver resections. World J Surg (2004) 2.04
Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer (2004) 2.03
Expression of Clostridium acetobutylicum butanol synthetic genes in Escherichia coli. Appl Microbiol Biotechnol (2007) 2.03
Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res (2009) 2.03
Wnt4 is a local repulsive cue that determines synaptic target specificity. Curr Biol (2007) 2.02